Bacillus coagulans SNZ 1969 - Clinical Research Data Summary

Bacillus coagulans SNZ 1969® Spore-Forming Probiotic Strain

Bacillus coagulans SNZ 1969® is a clinically studied ingredient used in the following Silver Fern™ Brand product:

Introduction

Bacillus coagulans SNZ 1969® is a spore-forming probiotic valued for its stability and ability to support digestive and microbial balance. Unlike many traditional probiotic strains that are sensitive to heat, moisture, and stomach acid, SNZ 1969® forms a natural protective spore that helps it remain stable during manufacturing, storage, and passage through the stomach. This stability supports the delivery of viable organisms to the intestines, where the spores can germinate and produce beneficial metabolites such as lactic acid, helping support a balanced gut environment and healthy microbial ecology.*

Like many spore-forming probiotics, SNZ 1969® is considered a transient organism, meaning it does not permanently colonize the gut but instead interacts with the existing microbiome during its passage through the digestive tract. This transient behavior supports its compatibility with the body's natural microbial ecosystem and makes it suitable for ongoing daily use.*

These are the studies for Bacillus coagulans SNZ 1969®. Below, we provided a summary of each key data for each study, along with a link to the complete clinical research.

  1. Summary of Study 1 – Full Study: https://www.tandfonline.com/doi/abs/10.1080/089106002760002694
  2. Summary of Study 2 – Full Study: https://www.ijhsr.org/IJHSR_Vol.12_Issue.3_March2022/IJHSR036.pdf
  3. Summary of Study 3 – Full Study: https://www.sciencedirect.com/science/article/abs/pii/S0271531701003670
  4. Summary of Study 4 – Full Study: https://www.ijbcp.com/index.php/ijbcp/article/view/5120
  5. Summary of Study 5 – Full Study: https://pubmed.ncbi.nlm.nih.gov/34119240/
  6. Summary of Study 6 – Full Study: https://jcdr.net/articles/PDF/19825/73063_CE
  7. Summary of Study 7 – Full Study: https://pubmed.ncbi.nlm.nih.gov/41262831/
  8. Summary of Study 8 – Full Study: https://www.researchgate.net/publication/325380610
  9. Summary of Study 9 – Full Study: https://www.longdom.org/open-access/cosupplementation-of-probiotic-bacillus-coagulans-snz-1969-and-whey-protein

Ingredient Manufacturer Link: https://www.sanzymebiologics.com/bacillus-coagulans/



Study 1 Summary

Complete Study Information: https://www.tandfonline.com/doi/abs/10.1080/089106002760002694

Spore-Forming Lactic Acid Bacterium Bacillus coagulans and Gut Microbial Balance
Ara, K. et al. Microbial Ecology in Health and Disease. 2002. 14:4–13.

This controlled human and animal study evaluated the characteristics and digestive-supporting effects of Bacillus coagulans SANK 70258 (a strain equivalent to SNZ 1969®). The human arm included 20 healthy adults over 6 weeks (2-week baseline, 2-week intake at ~1 × 10⁸ CFU/day, 2-week follow-up); animal arms explored constipation and high-protein diet models.

Key Findings (What the Study Showed)

  • Spores of B. coagulans SANK 70258 remained stable under acidic conditions and in the presence of bile salts, supporting viability during gastrointestinal transit
  • Increases in Bifidobacterium and Lactobacillus populations; reductions in certain protein-fermenting bacteria; modest shifts in fecal pH
  • Participants with lower baseline bowel frequency showed improvements in reported bowel movement frequency and stool form, along with improved subjective comfort following defecation
  • Reductions in fecal metabolites associated with protein fermentation (ammonia, indole, p-cresol) and decreases in certain fecal enzyme activity
  • In animal models, skin-related irritation markers were also reduced, explored as part of research into the gut–skin relationship

Why This Study Matters

This early study provides foundational evidence that B. coagulans SANK 70258/SNZ 1969® can remain stable through gastrointestinal conditions and support aspects of microbial balance and bowel function, including favorable shifts in fermentation metabolites.*

Reference Link: https://www.tandfonline.com/doi/abs/10.1080/089106002760002694



Study 2 Summary

Complete Study Information: https://www.ijhsr.org/IJHSR_Vol.12_Issue.3_March2022/IJHSR036.pdf

Randomized, Double-Blind, Placebo-Controlled Trial of Bacillus coagulans SNZ 1969® in Adults with Functional Digestive Discomfort
Soman, R.J. et al. International Journal of Health Sciences and Research. 2022; 12(3):253–264.

This randomized, double-blind, placebo-controlled trial evaluated B. coagulans SNZ 1969® (≥2 billion CFU/day) vs. placebo (calcium carbonate) in 60 adults (ages 18–60) reporting functional gastrointestinal discomfort over 30 days, with a 7-day follow-up after discontinuation.

Study Design Highlights

  • Study design: Randomized, double-blind, placebo-controlled
  • Participants: 60 adults (ages 18–60) with functional gastrointestinal discomfort
  • Dose: ≥2 billion CFU/day SNZ 1969® vs. calcium carbonate placebo
  • Duration: 30 days + 7-day follow-up
  • Assessments: Baseline, Day 15, Day 30, Day 37

Key Findings (What the Study Showed)

  • Greater improvements in overall digestive comfort scores vs. placebo over 30 days
  • Improvements in bloating, burping/belching, gas, upper-digestive discomfort, and occasional nausea vs. placebo
  • Higher participant satisfaction with digestive well-being in the probiotic group
  • Improvements in digestive comfort scores maintained during the 7-day follow-up after supplementation ended
  • Well tolerated; no serious adverse events; compliance exceeded 80%

Benefits of SNZ 1969® Demonstrated by This Study

Based directly on the clinical outcomes, SNZ 1969® at ≥2 billion CFU/day was shown to:
✓ Support greater improvements in digestive comfort scores vs. placebo over 30 days
✓ Support improvements in bloating, gas, upper-digestive discomfort, and nausea
✓ Maintain improved digestive comfort during 7-day post-discontinuation follow-up
✓ Be well tolerated with no serious adverse events and >80% compliance

Why This Study Matters

This randomized controlled trial provides clinical evidence that B. coagulans SNZ 1969® is well tolerated and may help support digestive comfort in adults experiencing occasional gastrointestinal symptoms.*

Reference Link: https://www.ijhsr.org/IJHSR_Vol.12_Issue.3_March2022/IJHSR036.pdf



Study 3 Summary

Complete Study Information: https://www.sciencedirect.com/science/article/abs/pii/S0271531701003670

Safety and Tolerability of Bacillus coagulans in Infants During the First Year of Life
Chandra, R.K. Nutrition Research. 2002; 22:65–69.

This prospective, randomized, double-blind, placebo-controlled study evaluated B. coagulans (100 million CFU/day) vs. placebo (sterile water) in 112 healthy full-term newborns in rural North India over 12 months, with weekly home visits and laboratory stool evaluation.

Study Design Highlights

  • Study design: Prospective, randomized, double-blind, placebo-controlled
  • Participants: 112 enrolled; 94 in final analysis
  • Dose: B. coagulans 100 million CFU/day vs. sterile water placebo
  • Duration: 12 months

Key Findings (What the Study Showed)

  • Infants receiving B. coagulans experienced fewer reported episodes involving gastrointestinal symptoms vs. placebo during the 12-month study
  • Episodes of gastrointestinal illness were shorter on average vs. the placebo group
  • Fewer total days with gastrointestinal symptoms across the full 12-month period
  • Body weight at one year slightly higher in the probiotic group (not statistically significant)
  • Well tolerated with no increase in adverse events; no differences in hydration outcomes

Why This Study Matters

This 12-month placebo-controlled infant study demonstrates that B. coagulans was well tolerated over long-term daily supplementation and was associated with differences in several measures related to digestive well-being, extending the evidence base for SNZ 1969® to early life.*

Reference Link: https://www.sciencedirect.com/science/article/abs/pii/S0271531701003670



Study 4 Summary

Complete Study Information: https://www.ijbcp.com/index.php/ijbcp/article/view/5120

Randomized, Double-Blind, Placebo-Controlled Trial of Bacillus coagulans SNZ 1969® in Adults with Chronic Gastrointestinal Symptoms
Soman RJ et al. International Journal of Basic & Clinical Pharmacology. 2022;11(6):550–558.

This randomized, double-blind, placebo-controlled trial evaluated B. coagulans SNZ 1969® (500 million CFU twice daily, 1 billion CFU/day total) vs. maltodextrin placebo in 92 adults experiencing chronic gastrointestinal discomfort over 60 days, with a follow-up assessment at Day 75. Quality of life was assessed using the SF-8 Health Survey.

Study Design Highlights

  • Study design: Randomized, double-blind, placebo-controlled
  • Participants: 92 adults with chronic gastrointestinal discomfort (two symptom patterns included)
  • Dose: SNZ 1969® 500 million CFU twice daily vs. maltodextrin placebo
  • Duration: 60 days + follow-up at Day 75

Key Findings (What the Study Showed)

  • Greater improvements in digestive symptom scores vs. placebo over 60 days
  • A larger proportion of participants in the probiotic group reported overall improvement in digestive symptoms vs. placebo
  • SF-8 quality-of-life scores (both physical and mental well-being) improved in the probiotic group; minimal change in placebo
  • Well tolerated: only one mild adverse event; no serious adverse events; no discontinuations

Benefits of SNZ 1969® Demonstrated by This Study

Based directly on the clinical outcomes, SNZ 1969® was shown to:
✓ Support greater improvements in digestive symptom scores over 60 days
✓ Support improvements in both physical and mental quality-of-life scores (SF-8)
✓ Be well tolerated over 60 days with no serious adverse events or discontinuations

Why This Study Matters

This randomized controlled trial extends the evidence for SNZ 1969® to 60 days in adults with chronic gastrointestinal symptoms, demonstrating improvements in digestive scores and quality of life — with a favorable safety profile.*

Reference Link: https://www.ijbcp.com/index.php/ijbcp/article/view/5120



Study 5 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/34119240/

Randomized, Double-Blind, Placebo-Controlled Trial of Bacillus coagulans SNZ 1969® and Digestive Regularity and Microbiome Markers
Randomized, placebo-controlled clinical trial.

This randomized, double-blind, placebo-controlled trial evaluated B. coagulans SNZ 1969® (1 × 10⁹ CFU/day) vs. maltodextrin placebo in 80 adults (ages 20–65) with mild intermittent bowel irregularity and low fruit/vegetable intake over 8 weeks, with a 2-week follow-up. Gut microbiome composition was assessed using 16S rRNA sequencing.

Study Design Highlights

  • Study design: Randomized, double-blind, placebo-controlled
  • Participants: 80 adults (ages 20–65) with mild intermittent bowel irregularity
  • Dose: SNZ 1969® 1 × 10⁹ CFU/day vs. maltodextrin placebo
  • Duration: 8 weeks + 2-week follow-up
  • Microbiome: 16S rRNA sequencing with multivariate statistical analysis

Key Findings (What the Study Showed)

  • Improvements in measured colonic transit time vs. placebo
  • Increased complete spontaneous bowel movements vs. placebo, with improvements observed early in the supplementation period
  • Improvements in bowel comfort scores including reduced straining and greater ease of bowel movements
  • Differences in relative abundance of several bacterial groups in the probiotic group; statistical associations between microbial changes and digestive function measures
  • Well tolerated: no serious adverse events; compliance exceeded 99%

Benefits of SNZ 1969® Demonstrated by This Study

Based directly on the clinical outcomes, SNZ 1969® at 1 billion CFU/day was shown to:
✓ Support improvements in colonic transit time
✓ Support increased complete spontaneous bowel movements
✓ Support improvements in straining and ease of bowel movement
✓ Show microbiome composition changes associated with digestive function improvements
✓ Achieve >99% participant compliance with no serious adverse events

Why This Study Matters

This study is notable for combining objective measures (colonic transit time via radiopaque markers), functional outcomes (bowel movements, comfort scores), and gut microbiome analysis — providing comprehensive evidence for SNZ 1969®'s role in supporting digestive regularity and microbiome balance.*

Reference Link: https://pubmed.ncbi.nlm.nih.gov/34119240/



Study 6 Summary

Complete Study Information: https://jcdr.net/articles/PDF/19825/73063_CE

Randomized, Double-Blind, Placebo-Controlled Trial of Bacillus coagulans SNZ 1969® in Young Children
Fernandes, M.J. et al. Journal of Clinical and Diagnostic Research. 2024; 18(9):FC01–FC06.

This randomized, double-blind, placebo-controlled trial evaluated B. coagulans SNZ 1969® (900 million CFU/day — 300 million CFU three times daily) vs. placebo in 46 completing children (ages 1–5) with nutritional vulnerability over 3 months.

Key Findings (What the Study Showed)

  • Children receiving SNZ 1969® experienced fewer total days of illness during the study period vs. placebo
  • Trends toward differences in the number of episodes involving gastrointestinal or respiratory symptoms
  • Trends toward fewer total days with gastrointestinal and respiratory symptoms
  • Well tolerated: no serious adverse events in the probiotic group; high compliance

Why This Study Matters

This pediatric randomized controlled trial extends SNZ 1969® evidence to children ages 1–5, demonstrating favorable tolerability and associations with health-related illness measures during a 3-month supplementation period.*

Reference Link: https://jcdr.net/articles/PDF/19825/73063_CE



Study 7 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/41262831/

Randomized, Double-Blind, Placebo-Controlled Trial of Bacillus coagulans SNZ 1969® and Immune Markers in Older Adults
Murthy, D.K. et al. Cureus. 2025;17(10):e94845.

This randomized, double-blind, placebo-controlled trial evaluated B. coagulans SNZ 1969® (2 billion CFU/day) vs. maltodextrin placebo in 60 adults aged 60–65 years with lower baseline NK cell activity over 12 weeks, with a 2-week safety follow-up. Immune markers were evaluated using NK cell cytotoxicity testing and ELISA-based immunoglobulin measurements.

Study Design Highlights

  • Study design: Randomized, double-blind, placebo-controlled
  • Participants: 60 adults (ages 60–65) with lower baseline NK cell activity
  • Dose: SNZ 1969® 2 billion CFU/day vs. maltodextrin placebo
  • Duration: 12 weeks + 2-week safety follow-up

Key Findings (What the Study Showed)

  • Greater increases in NK cell activity vs. placebo over the study period
  • Increases in both serum and salivary IgA vs. placebo
  • CRP and other measured immune markers remained stable — no increases in systemic inflammation markers
  • Trends toward fewer reported illness episodes and fewer total illness days (not statistically significant)
  • Well tolerated: no treatment-related adverse events; high compliance

Benefits of SNZ 1969® Demonstrated by This Study

Based directly on the clinical outcomes, SNZ 1969® at 2 billion CFU/day in older adults was shown to:
✓ Support increases in NK cell activity vs. placebo
✓ Support increases in both serum and salivary IgA (mucosal immune marker)
✓ Maintain stable CRP — no increase in inflammatory markers
✓ Be well tolerated over 12 weeks with no treatment-related adverse events

Why This Study Matters

This study provides immune-specific clinical evidence for SNZ 1969® in an older adult population, demonstrating improvements in NK cell activity and IgA levels — both relevant to immune system function — without increasing inflammation markers.*

Reference Link: https://pubmed.ncbi.nlm.nih.gov/41262831/



Study 8 Summary

Complete Study Information: https://www.researchgate.net/publication/325380610

Bacillus coagulans SNZ-1969® and Vaginal Microbiome Balance Markers
Usha Rani, V. et al. International Journal of Probiotics and Prebiotics. 2017;12(4):175–182.

This prospective clinical study evaluated oral supplementation with B. coagulans SNZ-1969® (120 million CFU three times daily for 21 days) alongside standard medical care vs. standard care alone in 120 women (ages 18–41) experiencing recurrent vaginal microbiome imbalance, assessing vaginal microbiome markers (Nugent score, vaginal pH), symptom-related measures, and recurrence during follow-up.

Key Findings (What the Study Showed)

  • Greater improvements in markers associated with vaginal microbial balance vs. standard care alone
  • Greater improvements in participant-reported symptom scores during the treatment period
  • Higher prevalence of lactobacilli and improvements in vaginal pH measures following probiotic treatment
  • Lower recurrence of symptoms during follow-up in the probiotic group vs. standard care alone
  • Well tolerated with no serious adverse events; considered safe for use alongside standard care

Why This Study Matters

This study contributes to research exploring the relationship between oral probiotics and the vaginal microbiome, suggesting that supplementation with SNZ-1969® may support microbial balance and reduce recurrence markers during follow-up.*

Reference Link: https://www.researchgate.net/publication/325380610



Study 9 Summary

Complete Study Information: https://www.longdom.org/open-access/cosupplementation-of-probiotic-bacillus-coagulans-snz-1969-and-whey-protein

Co-Supplementation of Bacillus coagulans SNZ 1969® and Whey Protein: Amino Acid Absorption Markers
Soman, R.J. et al. Journal of Nutrition & Food Sciences. 2024;14:51.

This randomized, double-blind, crossover trial evaluated B. coagulans SNZ 1969® (≥2 billion CFU/day) + whey protein (25 g/day) vs. whey protein alone in 22 completing healthy adults (ages 18–30) across two 14-day intervention periods with a 21-day washout. Plasma amino acid pharmacokinetics were assessed using LC-MS over 4 hours post-protein intake.

Study Design Highlights

  • Study design: Randomized, double-blind, crossover trial
  • Participants: 30 enrolled; 22 completed both intervention periods (ages 18–30)
  • Interventions: Whey protein (25 g/day) alone vs. whey protein + SNZ 1969® (≥2 billion CFU/day)
  • Duration: Two 14-day periods; 21-day washout

Key Findings (What the Study Showed)

  • Higher peak concentrations (Cmax) for several amino acids including arginine, cysteine, and histidine when consuming whey protein with SNZ 1969® vs. whey protein alone
  • Numerically shorter time to peak concentration (Tmax) for several amino acids in the probiotic group, suggesting differences in absorption timing
  • Lower occurrence of acneiform skin lesions during the period when participants consumed whey protein with SNZ 1969® vs. whey protein alone
  • Well tolerated: no treatment-related adverse events; no clinically significant changes in laboratory values or vital signs

Why This Study Matters

This crossover study provides emerging evidence that SNZ 1969® co-supplementation alongside whey protein may influence amino acid absorption markers, supporting digestive processes related to protein utilization while being well tolerated.*

Reference Link: https://www.longdom.org/open-access/cosupplementation-of-probiotic-bacillus-coagulans-snz-1969-and-whey-protein

Big-Picture Integration with Other Studies

  • Study 1: Controlled human and animal study showing spore stability, increases in Bifidobacterium and Lactobacillus, improvements in bowel frequency and comfort, and reductions in protein fermentation metabolites.
  • Study 2: 30-day RCT in 60 adults showing greater improvements in digestive comfort scores (bloating, gas, upper-digestive discomfort) vs. placebo with benefits maintained 7 days post-discontinuation.
  • Study 3: 12-month RCT in 94 infants showing fewer gastrointestinal symptom episodes, shorter duration, and fewer total symptom days vs. placebo with excellent tolerability.
  • Study 4: 60-day RCT in 92 adults with chronic gastrointestinal discomfort showing improvements in digestive symptom scores and SF-8 quality-of-life measures vs. placebo.
  • Study 5: 8-week RCT in 80 adults with bowel irregularity showing improvements in colonic transit time, complete spontaneous bowel movements, and bowel comfort scores with correlated microbiome changes vs. placebo.
  • Study 6: 3-month pediatric RCT in 46 children (ages 1–5) showing fewer total illness days and trends toward fewer gastrointestinal and respiratory symptom episodes vs. placebo.
  • Study 7: 12-week RCT in 60 older adults (ages 60–65) showing increases in NK cell activity and serum and salivary IgA without increasing CRP vs. placebo.
  • Study 8: Prospective study in 120 women showing greater improvements in vaginal microbiome balance markers, symptom scores, and lower recurrence vs. standard care alone.
  • Study 9: 14-day crossover trial in 22 healthy adults showing higher amino acid Cmax for arginine, cysteine, and histidine when SNZ 1969® was co-supplemented with whey protein vs. whey protein alone.

Bacillus coagulans SNZ 1969® Ingredient Summary & Real-World Relevance

Bacillus coagulans SNZ 1969® is a spore-forming probiotic recognized for its stability, versatility, and ability to support digestive and microbiome health. Unlike many traditional probiotic strains sensitive to heat, moisture, and stomach acid, SNZ 1969® forms a natural protective spore that helps it remain stable during manufacturing, storage, and gastrointestinal transit — supporting reliable delivery of viable organisms to the gut.*

Human research has explored SNZ 1969® across diverse populations including healthy adults, infants, children, older adults, and individuals experiencing gastrointestinal discomfort. These 9 studies — including multiple randomized controlled trials — suggest the strain may help support digestive comfort, bowel regularity, microbiome balance, and healthy immune system activity. Additional research has examined its influence on amino acid absorption markers and vaginal microbiome balance, highlighting the breadth of research on this versatile spore-forming probiotic.*

Ingredient Manufacturer Link: https://www.sanzymebiologics.com/bacillus-coagulans/

Bacillus coagulans SNZ 1969® is a clinically studied ingredient used in the following Silver Fern™ Brand product:

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.